NCT03215030: Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM
NCT01564537: Phase 3 - TOURMALINE-MM1 - Oral Ixazomib + Len/Dex Vs Placebo + Len/Dex RRMM
NCT02765854: Phase 2: Ixazomib and Dex Vs Ixazomib, Dex and Lenalidomide, With NFKB2 Rearrangement
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma
NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM
NCT01217957: Phase 1/2: A Study of Ixazomib in Combination With Lenalidomide and Low-Dex in NDMM
NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myel
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With RRMM
NCT00507442: Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat NDMM EVOLUTION
NCT00507416: Phase 3: Velcade,Thalidomide, Dexamethasone Vs Velcade, Dexamethasone Vs VMP (UPFRONT)
NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM
NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in NDMM
NCT00048230: Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With RRMM